Adult Immunization

Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.

Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found.

COVID-19 vaccine myths of many types remain potent enough to raise public health experts' concerns about Americans' willingness to roll up sleeves this year.

Adults saying they don't need immunization this fall have received the vaccines in the past, survey authors report, suggesting a lingering misinformation effect.

Your daily dose of the clinical news you may have missed.

New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.

Immune responses for both vaccines were noninferior when given at the same visit compared with separate administration among adults aged 50 years and older.

The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.

The new data amend that from prelicensure trials, which did not include fair representation of older adults and others more vulnerable to severe RSV disease.

The Bridge Access Program allowed Americans who are uninsured or underinsured to receive COVID-19 vaccination at not cost and was ended abruptly last month.